M. Boareto

Physiological variability in key Alzheimer's biomarkers in amyloid-positive clinical trial cohorts and the mechanistic basis of biomarker ratios

Background: Protein biomarkers in cerebrospinal fluid (CSF) and plasma have established themselves as essential tools for the diagnosis of neurological disorders and for disease monitoring, thanks to their accuracy and clinical validity. Outside their original intended context of use, protein biomarkers are increasingl...